Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial

Mariantonietta Cicoira, Aldo Pietro Maggioni, Roberto Latini, Simona Barlera, Elisa Carretta, Andras Janosi, Jordi Soler Soler, Inder Anand, Jay N. Cohn

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Aims: To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality. Methods and results: We performed a post-hoc analysis of 5010 patients from the Valsartan Heart Failure Trial. The end-points of the study were all-cause and cardiovascular mortality. Mortality rate was 27.2% in underweight patients (BMI < 22 kg/m2), 21.7% in normal weight patients (BMI 22-24.9 kg/m2), 17.9% in overweight patients (BMI 25-29.9 kg/m2) and 16.5% in obese patients (BMI > 30 kg/m2) (p < 0.0001). The rates of non-cardiovascular death did not differ among groups. The risk of death due to progressive heart failure was 3.4-fold higher in the underweight than in the obese patients (p < 0.0001). Normal weight, overweight and obese patients had lower risk of death as compared with underweight patients (p = 0.019, HR 0.76, 95% CI 0.61-0.96; p = 0.0005, HR 0.68, 95% CI 0.55-0.84; p = 0.003, HR 0.67, 95% CI 0.52-0.88, respectively) independently of symptoms, ventricular function, beta-blocker use, C-reactive protein and brain natriuretic peptide levels. Conclusions: In CHF patients a higher BMI is associated with a better prognosis independently of other clinical variables. The relationship between mortality and BMI is monotonically decreasing.

Original languageEnglish (US)
Pages (from-to)397-402
Number of pages6
JournalEuropean Journal of Heart Failure
Volume9
Issue number4
DOIs
StatePublished - Apr 1 2007

Fingerprint

Valsartan
Body Mass Index
Heart Failure
Thinness
Mortality
Ventricular Function
Brain Natriuretic Peptide
C-Reactive Protein

Keywords

  • Body mass index
  • Heart failure
  • Prognosis

Cite this

Body mass index, prognosis and mode of death in chronic heart failure : Results from the Valsartan Heart Failure Trial. / Cicoira, Mariantonietta; Maggioni, Aldo Pietro; Latini, Roberto; Barlera, Simona; Carretta, Elisa; Janosi, Andras; Soler Soler, Jordi; Anand, Inder; Cohn, Jay N.

In: European Journal of Heart Failure, Vol. 9, No. 4, 01.04.2007, p. 397-402.

Research output: Contribution to journalArticle

Cicoira, M, Maggioni, AP, Latini, R, Barlera, S, Carretta, E, Janosi, A, Soler Soler, J, Anand, I & Cohn, JN 2007, 'Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial', European Journal of Heart Failure, vol. 9, no. 4, pp. 397-402. https://doi.org/10.1016/j.ejheart.2006.10.016
Cicoira, Mariantonietta ; Maggioni, Aldo Pietro ; Latini, Roberto ; Barlera, Simona ; Carretta, Elisa ; Janosi, Andras ; Soler Soler, Jordi ; Anand, Inder ; Cohn, Jay N. / Body mass index, prognosis and mode of death in chronic heart failure : Results from the Valsartan Heart Failure Trial. In: European Journal of Heart Failure. 2007 ; Vol. 9, No. 4. pp. 397-402.
@article{4ef4939663164012a71dfb25cfbd6aba,
title = "Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial",
abstract = "Aims: To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality. Methods and results: We performed a post-hoc analysis of 5010 patients from the Valsartan Heart Failure Trial. The end-points of the study were all-cause and cardiovascular mortality. Mortality rate was 27.2{\%} in underweight patients (BMI < 22 kg/m2), 21.7{\%} in normal weight patients (BMI 22-24.9 kg/m2), 17.9{\%} in overweight patients (BMI 25-29.9 kg/m2) and 16.5{\%} in obese patients (BMI > 30 kg/m2) (p < 0.0001). The rates of non-cardiovascular death did not differ among groups. The risk of death due to progressive heart failure was 3.4-fold higher in the underweight than in the obese patients (p < 0.0001). Normal weight, overweight and obese patients had lower risk of death as compared with underweight patients (p = 0.019, HR 0.76, 95{\%} CI 0.61-0.96; p = 0.0005, HR 0.68, 95{\%} CI 0.55-0.84; p = 0.003, HR 0.67, 95{\%} CI 0.52-0.88, respectively) independently of symptoms, ventricular function, beta-blocker use, C-reactive protein and brain natriuretic peptide levels. Conclusions: In CHF patients a higher BMI is associated with a better prognosis independently of other clinical variables. The relationship between mortality and BMI is monotonically decreasing.",
keywords = "Body mass index, Heart failure, Prognosis",
author = "Mariantonietta Cicoira and Maggioni, {Aldo Pietro} and Roberto Latini and Simona Barlera and Elisa Carretta and Andras Janosi and {Soler Soler}, Jordi and Inder Anand and Cohn, {Jay N.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1016/j.ejheart.2006.10.016",
language = "English (US)",
volume = "9",
pages = "397--402",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Body mass index, prognosis and mode of death in chronic heart failure

T2 - Results from the Valsartan Heart Failure Trial

AU - Cicoira, Mariantonietta

AU - Maggioni, Aldo Pietro

AU - Latini, Roberto

AU - Barlera, Simona

AU - Carretta, Elisa

AU - Janosi, Andras

AU - Soler Soler, Jordi

AU - Anand, Inder

AU - Cohn, Jay N.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Aims: To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality. Methods and results: We performed a post-hoc analysis of 5010 patients from the Valsartan Heart Failure Trial. The end-points of the study were all-cause and cardiovascular mortality. Mortality rate was 27.2% in underweight patients (BMI < 22 kg/m2), 21.7% in normal weight patients (BMI 22-24.9 kg/m2), 17.9% in overweight patients (BMI 25-29.9 kg/m2) and 16.5% in obese patients (BMI > 30 kg/m2) (p < 0.0001). The rates of non-cardiovascular death did not differ among groups. The risk of death due to progressive heart failure was 3.4-fold higher in the underweight than in the obese patients (p < 0.0001). Normal weight, overweight and obese patients had lower risk of death as compared with underweight patients (p = 0.019, HR 0.76, 95% CI 0.61-0.96; p = 0.0005, HR 0.68, 95% CI 0.55-0.84; p = 0.003, HR 0.67, 95% CI 0.52-0.88, respectively) independently of symptoms, ventricular function, beta-blocker use, C-reactive protein and brain natriuretic peptide levels. Conclusions: In CHF patients a higher BMI is associated with a better prognosis independently of other clinical variables. The relationship between mortality and BMI is monotonically decreasing.

AB - Aims: To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality. Methods and results: We performed a post-hoc analysis of 5010 patients from the Valsartan Heart Failure Trial. The end-points of the study were all-cause and cardiovascular mortality. Mortality rate was 27.2% in underweight patients (BMI < 22 kg/m2), 21.7% in normal weight patients (BMI 22-24.9 kg/m2), 17.9% in overweight patients (BMI 25-29.9 kg/m2) and 16.5% in obese patients (BMI > 30 kg/m2) (p < 0.0001). The rates of non-cardiovascular death did not differ among groups. The risk of death due to progressive heart failure was 3.4-fold higher in the underweight than in the obese patients (p < 0.0001). Normal weight, overweight and obese patients had lower risk of death as compared with underweight patients (p = 0.019, HR 0.76, 95% CI 0.61-0.96; p = 0.0005, HR 0.68, 95% CI 0.55-0.84; p = 0.003, HR 0.67, 95% CI 0.52-0.88, respectively) independently of symptoms, ventricular function, beta-blocker use, C-reactive protein and brain natriuretic peptide levels. Conclusions: In CHF patients a higher BMI is associated with a better prognosis independently of other clinical variables. The relationship between mortality and BMI is monotonically decreasing.

KW - Body mass index

KW - Heart failure

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=33947356644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947356644&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2006.10.016

DO - 10.1016/j.ejheart.2006.10.016

M3 - Article

C2 - 17166768

AN - SCOPUS:33947356644

VL - 9

SP - 397

EP - 402

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 4

ER -